WASHINGTON, Dec 12 (Reuters) - U.S. health regulators are questioning whether ImClone Systems Inc's and Amgen Inc's proposed clinical trials are enough to show patients with a certain type of gene benefit more from two cancer drugs, according to documents released on Friday.
